Trevi Therapeutics shares are trading higher after BMO Capital initiated its coverage on the stock with an Outperform rating and announced a price target of $36.
benzinga_article
Trevi Therapeutics shares are trading higher after BMO Capital initiated its coverage on the stock with an Outperform rating and announced a price target of $36.
